Mesoblast Limited (NASDAQ:MESO - Get Free Report)'s share price gapped up before the market opened on Thursday . The stock had previously closed at $16.09, but opened at $16.86. Mesoblast shares last traded at $17.18, with a volume of 170,466 shares trading hands.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on the company. Jefferies Financial Group downgraded Mesoblast from a "buy" rating to a "hold" rating in a research report on Friday, July 18th. Cantor Fitzgerald upgraded Mesoblast to a "strong-buy" rating in a research report on Monday, March 31st. One investment analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $18.00.
Read Our Latest Stock Analysis on MESO
Mesoblast Stock Down 3.7%
The company has a quick ratio of 0.63, a current ratio of 0.96 and a debt-to-equity ratio of 0.22. The firm has a fifty day moving average price of $11.73 and a 200 day moving average price of $13.46.
Hedge Funds Weigh In On Mesoblast
Several hedge funds have recently bought and sold shares of MESO. BNP Paribas Financial Markets lifted its stake in shares of Mesoblast by 86,566.7% during the fourth quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company's stock worth $51,000 after purchasing an additional 2,597 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Mesoblast by 1,503.3% during the fourth quarter. Bank of America Corp DE now owns 290,728 shares of the company's stock valued at $5,756,000 after purchasing an additional 272,595 shares during the last quarter. GAMMA Investing LLC grew its holdings in Mesoblast by 1,174.2% in the 1st quarter. GAMMA Investing LLC now owns 85,513 shares of the company's stock worth $1,067,000 after buying an additional 78,802 shares in the last quarter. Quadrant Capital Group LLC lifted its position in Mesoblast by 41.1% in the fourth quarter. Quadrant Capital Group LLC now owns 6,496 shares of the company's stock worth $129,000 after purchasing an additional 1,891 shares during the period. Finally, Summit X LLC lifted its position in Mesoblast by 36.0% in the first quarter. Summit X LLC now owns 198,163 shares of the company's stock worth $2,473,000 after purchasing an additional 52,508 shares during the period. Hedge funds and other institutional investors own 1.43% of the company's stock.
About Mesoblast
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Featured Stories
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
